Source:http://linkedlifedata.com/resource/pubmed/id/12796788
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
2003-6-10
|
| pubmed:abstractText |
We analyzed predictive factors for the outcome of 113 acute myeloid leukemia patients receiving reduced-intensity conditioning prior to allogeneic hematopoietic stem cell transplantation (HSCT). Patients were ineligible for conventional-intensity HSCT. Conditioning consisted of fludarabine and 50% of the conventional dose of busulfan (n=93) or total body irradiation (n=20). The source of stem cells was blood in 102 patients, marrow in 10, and both in one. In total, 50 (44.2%) donors were HLA-matched siblings, 50 (44.2%) unrelated fully matched and 13 (11.5%) partially mismatched family (n=1) or unrelated (n=12) donors. In all, 107 (94.6%) patients showed neutrophil and platelet engraftment after a median time of 13.5 and 13 days. The probabilities of event-free survival (EFS) (median follow-up: 12 months) were 49% for patients with less than 5% blasts in the marrow, 24% for patients with 5-20% blasts (P=0.002) and 14% with >20% blasts (P<or=0.001). Death occurred because of relapse in 29 patients (25.6%), infection in 12 patients (10.6%), acute graft-versus-host disease in eight patients (7.0%) and organ toxicity in nine patients (7.9%). In multivariate analysis, higher number of blasts in the marrow, alternative donors and low Karnofsky performance score were independent adverse prognostic factors for EFS.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0268-3369
|
| pubmed:author |
pubmed-author:BeelenD WDW,
pubmed-author:BeyerJJ,
pubmed-author:BornhäuserMM,
pubmed-author:Cooperative German Transplant Study Group,
pubmed-author:EhningerGG,
pubmed-author:FauserAA,
pubmed-author:HöffkenKK,
pubmed-author:KiehlMM,
pubmed-author:KienastJJ,
pubmed-author:KleinS ASA,
pubmed-author:KrögerMM,
pubmed-author:MartinHH,
pubmed-author:RundeVV,
pubmed-author:SayerH GHG,
pubmed-author:Schaefer-EckartKK,
pubmed-author:ScheteligJJ,
pubmed-author:SchwerdtfegerRR,
pubmed-author:SiegertWW,
pubmed-author:TheuserCC
|
| pubmed:issnType |
Print
|
| pubmed:volume |
31
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1089-95
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:12796788-Adolescent,
pubmed-meshheading:12796788-Adult,
pubmed-meshheading:12796788-Aged,
pubmed-meshheading:12796788-Female,
pubmed-meshheading:12796788-Germany,
pubmed-meshheading:12796788-Graft Survival,
pubmed-meshheading:12796788-Graft vs Host Disease,
pubmed-meshheading:12796788-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:12796788-Humans,
pubmed-meshheading:12796788-Leukemia, Myeloid, Acute,
pubmed-meshheading:12796788-Male,
pubmed-meshheading:12796788-Middle Aged,
pubmed-meshheading:12796788-Prognosis,
pubmed-meshheading:12796788-Retrospective Studies,
pubmed-meshheading:12796788-Survival Rate,
pubmed-meshheading:12796788-Transplantation, Homologous,
pubmed-meshheading:12796788-Transplantation Conditioning
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor.
|
| pubmed:affiliation |
Klinik und Poliklinik für Innere Medizin II, Friedrich-Schiller-Universität Jena, Germany.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study
|